StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta (SRPT) Could See Exon 53 Approval in 2018, Peak Sales of ~$800M - William Blair
September 6, 2017 11:06 AM
William Blair analyst Tim Lugo weighed in on Sarepta Therapeutics (NASDAQ: SRPT) after the company announced positive interim 48-week data ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Sarepta (SRPT) SRP-4053 Data Provides 'Strong Validation' - SunTrust
September 6, 2017 11:54 AM
UPDATE: Sarepta Therapeutics (SRPT) PT Raised to $55 at Piper Jaffray
September 6, 2017 10:57 AM
Sarepta Therapeutics (SRPT): Needham & Company Highlights 2 Significant Positive Implications from Dolodiresen Data
September 6, 2017 8:42 AM
Sarepta Therapeutics to Ring Nasdaq Stock Market Closing Bell in Recognition of World Duchenne Awareness Day
September 6, 2017 8:30 AM
Sarepta (SRPT) SRP-4053 Data Strengthen Case for Exon Expansion Approach - Baird; Reit. OP, $101 PT
September 6, 2017 8:30 AM
Energy shares lead broad rebound on Wall Street
September 6, 2017 7:41 AM
Sarepta Therapeutics (SRPT) Phase 1/2 Study of Golodirsen in DMD Hits Statistical Significance on all Primary and Secondary Endpoints
September 6, 2017 7:05 AM
Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable
September 6, 2017 7:00 AM
